NCCN Guidelines in ES-SCLC, Eligibility Criteria, and Communicating Survival Benefit

Dr. Shields confirms that NCCN guidelines now recommend lurbinectedin plus atezolizumab as preferred maintenance therapy following 4 cycles of chemotherapy and immunotherapy, with the specific footnote limiting this to patients with ECOG performance status 0 to 1 and no history of brain metastases. She strictly follows the brain metastasis exclusion criteria for treatment-naive patients but notes this restriction wasn't applied in second or third-line relapse settings.

For patients with oligo-progression in the brain after achieving durable responses, she pursues stereotactic radiosurgery while continuing the maintenance regimen, switching strategies only if multiple brain lesions develop.

Dr. Sands addresses how high-risk patients with treated brain metastases who achieved stability weren't included in IMforte, representing patients at elevated metastatic risk where escalation might be considered. He notes the regimen doesn't demonstrate CNS efficacy, so isolated brain progression with controlled systemic disease warrants stereotactic radiation while continuing the same systemic therapy.

Regarding communicating the 3.2-month induction benefit to patients, Dr. Chiang explains she avoids specific numbers, instead discussing best-case and worst-case scenarios broadly. She emphasizes that many oncologists don't recognize that IMforte's reported survival benefit excludes induction time, requiring addition of 3.2 months when comparing against other first-line regimens like IMpower133 or CASPIAN, while acknowledging the trial's attrition removed higher-risk patients from both arms.